
Tag: ALKtALK
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-

ALKtALK: Dr. Jonathan Riess
ALKtALK with Dr. Jonathan Riess Join us live to be informed and empowered by a data-driven conversation focused on where the science is now and where it may be headed
-

ALKtALK: Dr. Alex Drilon
New Data, New Directions: Neladalkib (NVL-655) and Precision Oncology in ALK-positive Cancer Alexander Drilon, MD, is a thoracic oncologist and Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer
-

ALKtALK: Treatment Roundtables
ALKtALK presents: tALKing About Treatment: Roundtable Discussion Groups Sunday, February 15th is our annual treatment roundtable discussion — a longtime favorite within the ALK community. Treatment is not a one-size-fits-all
-

Start 2026 with ALKtALK: A conversation with Dr. Alice Shaw
Sunday, January 11th. Dr. Alice Shaw is a world-renowned thoracic oncologist and one of the most influential leaders in lung cancer research. Often referred to as the “Queen of ALK,”
-

ALKtALK: Break Through Cancer’s Jesse Boehm Returns to ALKtALK with information, insight, and hope.
Sunday, December 14th, Jesse Boehm returns to ALKtALK with an informative update on Break Through Cancer’s PowerRD 2 Cure ALK+ Lung Cancer TeamLab. If you’re hearing about Break Through Cancer for the first time,
-

ALKtALK: Holiday Stress Health
Who: Dr. Karen Schurgin 📅 When: Sunday, December 7th, 7pm ET📺 Replay: Recording will be available on the ALK Positive YouTube channel Don’t miss this ALKtALK with Dr. Karen Schurgin
-

Live from ASCO with Break Through Cancer
🚨 LIVE from ASCO – You’re Invited! 🚨 We’re kicking off ALK Positive Awareness Month 2025 with a special ALKtALK, featuring a research update from Break Through Cancer and a
-

Let’s talk meds, interactions, and whole-person care in thoracic oncology.Join ALKtALK for a discussion on Managing Meds & More: The Pharmacist’s Role in ALK+ Cancer
